Share Price and Basic Stock Data
Last Updated: December 24, 2025, 5:41 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Pharmaids Pharmaceuticals Ltd operates within the pharmaceuticals industry, reporting a current market capitalization of ₹171 Cr and a share price of ₹48.4. The company has faced significant revenue challenges, with sales recorded at ₹0 for multiple quarters up to September 2023. However, a notable uptick in revenue was observed in the subsequent quarters, with sales rising to ₹5.81 Cr in March 2024 and reaching ₹6.66 Cr by June 2025. Despite these improvements, the trailing twelve months (TTM) revenue stood at ₹25 Cr, indicating a slow recovery trajectory. The company’s ability to generate consistent revenue remains uncertain, particularly given the backdrop of zero sales in previous quarters. This revenue volatility underscores the need for strategic adjustments to enhance operational performance and market penetration.
Profitability and Efficiency Metrics
Pharmaids Pharmaceuticals has reported significant losses, with a net profit of -₹16 Cr for the current fiscal year. The operating profit margin (OPM) stood at -81.08%, reflecting substantial operational inefficiencies. The company has consistently recorded negative operating profits, highlighting ongoing challenges in managing costs relative to sales. The interest coverage ratio (ICR) was reported at -6.06x, indicating that the company is struggling to meet its interest obligations from its earnings. Furthermore, the return on equity (ROE) is relatively low at 16.3%, while the return on capital employed (ROCE) is slightly better at 17.4%. These metrics suggest that while the company is generating some returns on equity, the overall profitability landscape is concerning due to persistent losses and operational inefficiencies.
Balance Sheet Strength and Financial Ratios
Pharmaids Pharmaceuticals’ balance sheet reflects a total borrowing of ₹20 Cr, against reserves of ₹17 Cr, indicating a reliance on debt financing to support operations. The current ratio is reported at 0.77, suggesting potential liquidity issues, as it falls below the ideal benchmark of 1.0. Notably, the price-to-book value (P/BV) ratio is high at 4.08x, which may indicate overvaluation in relation to the company’s book value per share of ₹16.82 as of March 2025. The company’s total assets stood at ₹120 Cr, with fixed assets accounting for ₹77 Cr, indicating a significant investment in long-term assets. However, the asset turnover ratio is low at 0.18%, reflecting inefficiencies in utilizing assets to generate revenue. Overall, while the balance sheet shows some investment in fixed assets, the high debt levels and low liquidity raise concerns regarding the company’s financial health.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Pharmaids Pharmaceuticals indicates a significant shift in promoter ownership, which declined from 16.54% in December 2022 to 5.14% by June 2025, while public ownership rose to 67%. This shift could reflect declining confidence from promoters and a growing presence of retail investors. The number of shareholders has remained relatively stable, with 8,027 shareholders as of September 2025. The significant public ownership might provide some stability, but the declining promoter stake raises questions about the long-term strategic direction of the company. The absence of institutional investors (both FIIs and DIIs) further suggests a lack of confidence from larger market players. This dynamic could impact the company’s ability to attract future investment and support, hindering its recovery efforts.
Outlook, Risks, and Final Insight
Pharmaids Pharmaceuticals faces a challenging outlook, primarily due to its ongoing operational losses and significant debt levels. The company’s ability to generate consistent revenues remains uncertain, which poses risks to its financial stability. Key strengths include the recent uptick in sales and a strong return on equity, indicating potential for recovery if operational efficiencies are improved. However, the high P/BV ratio and liquidity challenges present substantial risks. The company must address these inefficiencies to regain investor confidence and stabilize its financial position. Future scenarios could include a successful turnaround if operational strategies are effectively implemented, but failure to do so may lead to further declines in market confidence and financial health.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 135 Cr. | 107 | 231/84.3 | 29.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,754 Cr. | 438 | 479/192 | 98.4 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.9 Cr. | 47.0 | 88.6/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 48.7 Cr. | 33.3 | 35.0/17.0 | 116 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,184.99 Cr | 1,154.23 | 53.11 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 5.81 | 4.73 | 5.24 | 4.71 | 4.77 | 6.66 |
| Expenses | 0.54 | 0.69 | 8.60 | 1.61 | 1.02 | 2.45 | 11.39 | 8.14 | 7.80 | 7.60 | 8.67 | 12.06 |
| Operating Profit | -0.54 | -0.69 | -8.60 | -1.61 | -1.02 | -2.43 | -5.58 | -3.41 | -2.56 | -2.89 | -3.90 | -5.40 |
| OPM % | -12,150.00% | -96.04% | -72.09% | -48.85% | -61.36% | -81.76% | -81.08% | |||||
| Other Income | 0.00 | 0.00 | 0.00 | 0.41 | -0.26 | 0.76 | 0.12 | -0.07 | -0.06 | 0.00 | 0.13 | 0.04 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.77 | 0.26 | 0.33 | 0.48 | 1.01 | 1.20 |
| Depreciation | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | 0.04 | 0.63 | 0.57 | 0.61 | 0.64 | 0.62 | 0.61 |
| Profit before tax | -0.55 | -0.70 | -8.60 | -1.21 | -1.29 | -1.73 | -6.86 | -4.31 | -3.56 | -4.01 | -5.40 | -7.17 |
| Tax % | 0.00% | 0.00% | -28.37% | 7.44% | -60.47% | -33.53% | -7.73% | -27.38% | -28.09% | -24.94% | -11.11% | -25.94% |
| Net Profit | -0.55 | -0.71 | -6.16 | -1.30 | -0.50 | -1.15 | -6.33 | -3.12 | -2.56 | -3.01 | -4.80 | -5.31 |
| EPS in Rs | -0.53 | -0.54 | -2.87 | -0.61 | -0.23 | -0.54 | -1.57 | -0.76 | -0.63 | -0.55 | -1.12 | -1.40 |
Last Updated: August 20, 2025, 5:15 am
Below is a detailed analysis of the quarterly data for Pharmaids Pharmaceuticals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 6.66 Cr.. The value appears strong and on an upward trend. It has increased from 4.77 Cr. (Mar 2025) to 6.66 Cr., marking an increase of 1.89 Cr..
- For Expenses, as of Jun 2025, the value is 12.06 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 8.67 Cr. (Mar 2025) to 12.06 Cr., marking an increase of 3.39 Cr..
- For Operating Profit, as of Jun 2025, the value is -5.40 Cr.. The value appears to be declining and may need further review. It has decreased from -3.90 Cr. (Mar 2025) to -5.40 Cr., marking a decrease of 1.50 Cr..
- For OPM %, as of Jun 2025, the value is -81.08%. The value appears strong and on an upward trend. It has increased from -81.76% (Mar 2025) to -81.08%, marking an increase of 0.68%.
- For Other Income, as of Jun 2025, the value is 0.04 Cr.. The value appears to be declining and may need further review. It has decreased from 0.13 Cr. (Mar 2025) to 0.04 Cr., marking a decrease of 0.09 Cr..
- For Interest, as of Jun 2025, the value is 1.20 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.01 Cr. (Mar 2025) to 1.20 Cr., marking an increase of 0.19 Cr..
- For Depreciation, as of Jun 2025, the value is 0.61 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.62 Cr. (Mar 2025) to 0.61 Cr., marking a decrease of 0.01 Cr..
- For Profit before tax, as of Jun 2025, the value is -7.17 Cr.. The value appears to be declining and may need further review. It has decreased from -5.40 Cr. (Mar 2025) to -7.17 Cr., marking a decrease of 1.77 Cr..
- For Tax %, as of Jun 2025, the value is -25.94%. The value appears to be improving (decreasing) as expected. It has decreased from -11.11% (Mar 2025) to -25.94%, marking a decrease of 14.83%.
- For Net Profit, as of Jun 2025, the value is -5.31 Cr.. The value appears to be declining and may need further review. It has decreased from -4.80 Cr. (Mar 2025) to -5.31 Cr., marking a decrease of 0.51 Cr..
- For EPS in Rs, as of Jun 2025, the value is -1.40. The value appears to be declining and may need further review. It has decreased from -1.12 (Mar 2025) to -1.40, marking a decrease of 0.28.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:48 am
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|
| Sales | 4 | 0 | 15 | 19 | 25 |
| Expenses | 4 | 10 | 27 | 32 | 42 |
| Operating Profit | 0 | -10 | -12 | -13 | -17 |
| OPM % | 3% | -82% | -66% | -71% | |
| Other Income | 0 | 0 | 0 | 0 | 3 |
| Interest | 0 | 0 | 2 | 2 | 4 |
| Depreciation | 0 | 0 | 2 | 2 | 2 |
| Profit before tax | 0 | -10 | -16 | -17 | -20 |
| Tax % | 0% | -24% | -24% | -22% | |
| Net Profit | 0 | -8 | -12 | -14 | -16 |
| EPS in Rs | 0.15 | -3.52 | -2.26 | -3.06 | -3.76 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2023-2024 | 2024-2025 |
|---|---|---|
| YoY Net Profit Growth (%) | -50.00% | -16.67% |
| Change in YoY Net Profit Growth (%) | 0.00% | 33.33% |
Pharmaids Pharmaceuticals Ltd has shown a consistent positive trend in YoY Net Profit Growth (%) in the last 2 years from 2023-2024 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 70% |
| TTM: | 102% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -33% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 35% |
| 5 Years: | 70% |
| 3 Years: | 67% |
| 1 Year: | 53% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -20% |
| Last Year: | -16% |
Last Updated: September 5, 2025, 12:30 pm
Balance Sheet
Last Updated: December 4, 2025, 1:49 am
| Month | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|
| Equity Capital | 10 | 21 | 35 | 35 | 35 |
| Reserves | -2 | 1 | 37 | 24 | 17 |
| Borrowings | 0 | 0 | 9 | 39 | 20 |
| Other Liabilities | 2 | 2 | 11 | 22 | 26 |
| Total Liabilities | 11 | 25 | 91 | 120 | 98 |
| Fixed Assets | 0 | 0 | 63 | 77 | 55 |
| CWIP | 0 | 2 | 7 | 5 | 3 |
| Investments | 0 | 3 | 0 | 0 | 0 |
| Other Assets | 11 | 19 | 21 | 39 | 41 |
| Total Assets | 11 | 25 | 91 | 120 | 98 |
Below is a detailed analysis of the balance sheet data for Pharmaids Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 35.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 35.00 Cr..
- For Reserves, as of Sep 2025, the value is 17.00 Cr.. The value appears to be declining and may need further review. It has decreased from 24.00 Cr. (Mar 2025) to 17.00 Cr., marking a decrease of 7.00 Cr..
- For Borrowings, as of Sep 2025, the value is 20.00 Cr.. The value appears to be improving (decreasing). However, Borrowings exceed Reserves, which may signal higher financial risk. It has decreased from 39.00 Cr. (Mar 2025) to 20.00 Cr., marking a decrease of 19.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 26.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 22.00 Cr. (Mar 2025) to 26.00 Cr., marking an increase of 4.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 98.00 Cr.. The value appears to be improving (decreasing). It has decreased from 120.00 Cr. (Mar 2025) to 98.00 Cr., marking a decrease of 22.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 55.00 Cr.. The value appears to be declining and may need further review. It has decreased from 77.00 Cr. (Mar 2025) to 55.00 Cr., marking a decrease of 22.00 Cr..
- For CWIP, as of Sep 2025, the value is 3.00 Cr.. The value appears to be declining and may need further review. It has decreased from 5.00 Cr. (Mar 2025) to 3.00 Cr., marking a decrease of 2.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 41.00 Cr.. The value appears strong and on an upward trend. It has increased from 39.00 Cr. (Mar 2025) to 41.00 Cr., marking an increase of 2.00 Cr..
- For Total Assets, as of Sep 2025, the value is 98.00 Cr.. The value appears to be declining and may need further review. It has decreased from 120.00 Cr. (Mar 2025) to 98.00 Cr., marking a decrease of 22.00 Cr..
However, the Borrowings (20.00 Cr.) are higher than the Reserves (17.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Free Cash Flow | 0.00 | -10.00 | -21.00 | -52.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Debtor Days | 124 | 65 | 59 | |
| Inventory Days | 91 | 0 | 112 | 359 |
| Days Payable | 236 | 159 | 480 | |
| Cash Conversion Cycle | -21 | 17 | -63 | |
| Working Capital Days | -18 | -69 | -160 | |
| ROCE % | -64% | -26% | -17% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -3.05 | -3.56 | -5.86 | 0.14 |
| Diluted EPS (Rs.) | -3.05 | -3.56 | -5.86 | 0.14 |
| Cash EPS (Rs.) | -3.14 | -2.87 | -3.52 | 0.15 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 16.82 | 19.99 | 10.47 | 8.44 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 16.82 | 19.99 | 10.47 | 8.44 |
| Revenue From Operations / Share (Rs.) | 5.51 | 4.28 | 0.00 | 3.84 |
| PBDIT / Share (Rs.) | -3.59 | -3.50 | -4.61 | 0.14 |
| PBIT / Share (Rs.) | -4.28 | -3.98 | -4.62 | 0.13 |
| PBT / Share (Rs.) | -4.90 | -4.43 | -4.62 | 0.13 |
| Net Profit / Share (Rs.) | -3.83 | -3.36 | -3.52 | 0.14 |
| NP After MI And SOA / Share (Rs.) | -3.06 | -2.26 | -3.52 | 0.14 |
| PBDIT Margin (%) | -65.06 | -81.57 | 0.00 | 3.86 |
| PBIT Margin (%) | -77.61 | -92.99 | 0.00 | 3.63 |
| PBT Margin (%) | -88.85 | -103.37 | 0.00 | 3.56 |
| Net Profit Margin (%) | -69.44 | -78.36 | 0.00 | 3.68 |
| NP After MI And SOA Margin (%) | -55.41 | -52.72 | 0.00 | 3.68 |
| Return on Networth / Equity (%) | -18.16 | -11.05 | -33.64 | 1.67 |
| Return on Capital Employeed (%) | -16.56 | -17.61 | -44.09 | 1.64 |
| Return On Assets (%) | -8.99 | -8.72 | -30.72 | 1.30 |
| Long Term Debt / Equity (X) | 0.50 | 0.04 | 0.00 | 0.00 |
| Total Debt / Equity (X) | 0.59 | 0.07 | 0.00 | 0.00 |
| Asset Turnover Ratio (%) | 0.18 | 0.26 | 0.00 | 0.00 |
| Current Ratio (X) | 0.77 | 1.17 | 8.23 | 1.09 |
| Quick Ratio (X) | 0.35 | 0.85 | 8.23 | 0.72 |
| Inventory Turnover Ratio (X) | 2.47 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | -6.06 | -7.86 | -2135.71 | 55.63 |
| Interest Coverage Ratio (Post Tax) (X) | -5.42 | -6.55 | -1631.24 | 54.05 |
| Enterprise Value (Cr.) | 271.01 | 182.39 | 34.01 | 12.44 |
| EV / Net Operating Revenue (X) | 13.94 | 12.07 | 0.00 | 3.16 |
| EV / EBITDA (X) | -21.42 | -14.79 | -3.44 | 81.73 |
| MarketCap / Net Operating Revenue (X) | 12.45 | 12.14 | 0.00 | 3.26 |
| Price / BV (X) | 4.08 | 2.55 | 2.08 | 1.48 |
| Price / Net Operating Revenue (X) | 12.45 | 12.14 | 0.00 | 3.26 |
| EarningsYield | -0.04 | -0.04 | -0.16 | 0.01 |
After reviewing the key financial ratios for Pharmaids Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -3.05. This value is below the healthy minimum of 5. It has increased from -3.56 (Mar 24) to -3.05, marking an increase of 0.51.
- For Diluted EPS (Rs.), as of Mar 25, the value is -3.05. This value is below the healthy minimum of 5. It has increased from -3.56 (Mar 24) to -3.05, marking an increase of 0.51.
- For Cash EPS (Rs.), as of Mar 25, the value is -3.14. This value is below the healthy minimum of 3. It has decreased from -2.87 (Mar 24) to -3.14, marking a decrease of 0.27.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 16.82. It has decreased from 19.99 (Mar 24) to 16.82, marking a decrease of 3.17.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 16.82. It has decreased from 19.99 (Mar 24) to 16.82, marking a decrease of 3.17.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 5.51. It has increased from 4.28 (Mar 24) to 5.51, marking an increase of 1.23.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -3.59. This value is below the healthy minimum of 2. It has decreased from -3.50 (Mar 24) to -3.59, marking a decrease of 0.09.
- For PBIT / Share (Rs.), as of Mar 25, the value is -4.28. This value is below the healthy minimum of 0. It has decreased from -3.98 (Mar 24) to -4.28, marking a decrease of 0.30.
- For PBT / Share (Rs.), as of Mar 25, the value is -4.90. This value is below the healthy minimum of 0. It has decreased from -4.43 (Mar 24) to -4.90, marking a decrease of 0.47.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -3.83. This value is below the healthy minimum of 2. It has decreased from -3.36 (Mar 24) to -3.83, marking a decrease of 0.47.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -3.06. This value is below the healthy minimum of 2. It has decreased from -2.26 (Mar 24) to -3.06, marking a decrease of 0.80.
- For PBDIT Margin (%), as of Mar 25, the value is -65.06. This value is below the healthy minimum of 10. It has increased from -81.57 (Mar 24) to -65.06, marking an increase of 16.51.
- For PBIT Margin (%), as of Mar 25, the value is -77.61. This value is below the healthy minimum of 10. It has increased from -92.99 (Mar 24) to -77.61, marking an increase of 15.38.
- For PBT Margin (%), as of Mar 25, the value is -88.85. This value is below the healthy minimum of 10. It has increased from -103.37 (Mar 24) to -88.85, marking an increase of 14.52.
- For Net Profit Margin (%), as of Mar 25, the value is -69.44. This value is below the healthy minimum of 5. It has increased from -78.36 (Mar 24) to -69.44, marking an increase of 8.92.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -55.41. This value is below the healthy minimum of 8. It has decreased from -52.72 (Mar 24) to -55.41, marking a decrease of 2.69.
- For Return on Networth / Equity (%), as of Mar 25, the value is -18.16. This value is below the healthy minimum of 15. It has decreased from -11.05 (Mar 24) to -18.16, marking a decrease of 7.11.
- For Return on Capital Employeed (%), as of Mar 25, the value is -16.56. This value is below the healthy minimum of 10. It has increased from -17.61 (Mar 24) to -16.56, marking an increase of 1.05.
- For Return On Assets (%), as of Mar 25, the value is -8.99. This value is below the healthy minimum of 5. It has decreased from -8.72 (Mar 24) to -8.99, marking a decrease of 0.27.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.50. This value is within the healthy range. It has increased from 0.04 (Mar 24) to 0.50, marking an increase of 0.46.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.59. This value is within the healthy range. It has increased from 0.07 (Mar 24) to 0.59, marking an increase of 0.52.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.18. It has decreased from 0.26 (Mar 24) to 0.18, marking a decrease of 0.08.
- For Current Ratio (X), as of Mar 25, the value is 0.77. This value is below the healthy minimum of 1.5. It has decreased from 1.17 (Mar 24) to 0.77, marking a decrease of 0.40.
- For Quick Ratio (X), as of Mar 25, the value is 0.35. This value is below the healthy minimum of 1. It has decreased from 0.85 (Mar 24) to 0.35, marking a decrease of 0.50.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.47. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 24) to 2.47, marking an increase of 2.47.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -6.06. This value is below the healthy minimum of 3. It has increased from -7.86 (Mar 24) to -6.06, marking an increase of 1.80.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -5.42. This value is below the healthy minimum of 3. It has increased from -6.55 (Mar 24) to -5.42, marking an increase of 1.13.
- For Enterprise Value (Cr.), as of Mar 25, the value is 271.01. It has increased from 182.39 (Mar 24) to 271.01, marking an increase of 88.62.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 13.94. This value exceeds the healthy maximum of 3. It has increased from 12.07 (Mar 24) to 13.94, marking an increase of 1.87.
- For EV / EBITDA (X), as of Mar 25, the value is -21.42. This value is below the healthy minimum of 5. It has decreased from -14.79 (Mar 24) to -21.42, marking a decrease of 6.63.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 12.45. This value exceeds the healthy maximum of 3. It has increased from 12.14 (Mar 24) to 12.45, marking an increase of 0.31.
- For Price / BV (X), as of Mar 25, the value is 4.08. This value exceeds the healthy maximum of 3. It has increased from 2.55 (Mar 24) to 4.08, marking an increase of 1.53.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 12.45. This value exceeds the healthy maximum of 3. It has increased from 12.14 (Mar 24) to 12.45, marking an increase of 0.31.
- For EarningsYield, as of Mar 25, the value is -0.04. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded -0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Pharmaids Pharmaceuticals Ltd:
- Net Profit Margin: -69.44%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -16.56% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -18.16% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -5.42
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.35
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 53.11)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.59
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -69.44%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Unit 201, Brigade Rubix, 2nd Floor, 20/14, HMT Factory Main Road, Bengaluru Karnataka 560013 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Shankarappa Nagaraja Vinaya Babu | Chairman, Non Ind & Non Exe Director |
| Ms. Mini Manikantan | Executive Director |
| Mr. Venu Madhava Kaparthy | Executive Director |
| Mr. Shreedhara Shetty | Non Exe.Non Ind.Director |
| Mr. Methuku Nagesh | Independent Director |
| Mr. P N Vijay | Independent Director |
| Mr. Mopperthy Sudheer | Independent Director |
FAQ
What is the intrinsic value of Pharmaids Pharmaceuticals Ltd?
Pharmaids Pharmaceuticals Ltd's intrinsic value (as of 24 December 2025) is 29.33 which is 41.34% lower the current market price of 50.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 176 Cr. market cap, FY2025-2026 high/low of 85.0/42.0, reserves of ₹17 Cr, and liabilities of 98 Cr.
What is the Market Cap of Pharmaids Pharmaceuticals Ltd?
The Market Cap of Pharmaids Pharmaceuticals Ltd is 176 Cr..
What is the current Stock Price of Pharmaids Pharmaceuticals Ltd as on 24 December 2025?
The current stock price of Pharmaids Pharmaceuticals Ltd as on 24 December 2025 is 50.0.
What is the High / Low of Pharmaids Pharmaceuticals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Pharmaids Pharmaceuticals Ltd stocks is 85.0/42.0.
What is the Stock P/E of Pharmaids Pharmaceuticals Ltd?
The Stock P/E of Pharmaids Pharmaceuticals Ltd is .
What is the Book Value of Pharmaids Pharmaceuticals Ltd?
The Book Value of Pharmaids Pharmaceuticals Ltd is 14.7.
What is the Dividend Yield of Pharmaids Pharmaceuticals Ltd?
The Dividend Yield of Pharmaids Pharmaceuticals Ltd is 0.00 %.
What is the ROCE of Pharmaids Pharmaceuticals Ltd?
The ROCE of Pharmaids Pharmaceuticals Ltd is 17.4 %.
What is the ROE of Pharmaids Pharmaceuticals Ltd?
The ROE of Pharmaids Pharmaceuticals Ltd is 16.3 %.
What is the Face Value of Pharmaids Pharmaceuticals Ltd?
The Face Value of Pharmaids Pharmaceuticals Ltd is 10.0.